Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award PDF Print E-mail
Thursday, 17 September 2009 10:52
In a recent Medical News Today article, it was reported that Thomas A. Medsger Jr., M.D.,  Gerald P. Rodnan Professor of Medicine, University of Pittsburgh School of Medicine, received the Scleroderma Foundation's Lifetime Achievement Award in recognition of his service to the Scleroderma community. The award is the foundation's highest honor and is presented to individuals who have devoted a minimum of 20 years of service, either as a volunteer or professional, to the Scleroderma community.

Dr. Medsger has served as chief of the University of Pittsburgh's Division of Rheumatology and Clinical Immunology, and director of the Scleroderma Research Program and UPMC's Scleroderma Clinic. His primary clinical and investigative interest is in Scleroderma and other connective tissue diseases.

In 2001 and 2005, Dr. Medsger was the recipient of the Scleroderma Foundation's Doctor of the Year award. He also has been designated as one of the Best Doctors in America by American Health Magazine for the past two decades and was the recipient of the American College of Rheumatology's Distinguished Rheumatologist Award. Recently, he had the title of "Master" conferred upon him by the American College of Rheumatology - a title awarded to members of high professional competence, ethics and moral standing who have significantly furthered the science of rheumatology.

Dr. Medsger currently serves as the Scleroderma Foundation Western Pennsylvania Chapter's treasurer and interim president. He has written numerous articles for the Foundation's Voice magazine and has published more than 300 journal articles about scleroderma and related diseases.

Read the full article here.
 
More articles :

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» Our Donors

The Scleroderma Care Foundation wishes to express our appreciation and gratitude for the generosity and support extended to us, by all of our donors to date, and the list keeps on growing. Your contributions have all been incredibly helpful and...

» Frequency of Sexual Dysfunction In Women With Rheumatic Diseases

Sexuality is part of human life and of quality of life, accounting for individual well-being. It relates not only to sexual intercourse itself, but also to a whole spectrum that ranges from self-image and self-valuing to relationship with the...

» Treatment for Pulmonary Arterial Hypertension Cleared

has recently reported in its that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to...

» Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

Jo N. Fleming, Richard A. Nash, D. O. McLeod, David F. Fiorentino, Howard M. Shulman, M. Kari Connolly, Jerry A. Molitor, GretchenHenstorf, Robert Lafyatis, David K. Pritchard, Lawrence D. Adams, Daniel E. Furst, Stephen M....

» Active Biotech Presents Data regarding the 57-57 Project at EULAR

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data from an exploratory clinical trial in Systemic Lupus Erythematosus (SLE) patients at the Annual European Congress of Rheumatology EULAR 2011, an international event for specialists in the...